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ORIGINAL ARTICLEThe Reliability of Disease Activity Score in 28 Joints–C-Reactive
Protein Might Be Overestimated in a Subgroup of
Rheumatoid Arthritis Patients, When the Score Is
Solely Based on Subjective Parameters
A Cross-sectional, Exploratory StudyInger Marie Jensen Hansen, PhD, DMSci,*†‡ Rikke Asmussen Andreasen, MD,*
Mark Nam van Bui Hansen,§ and Amir Emamifar, MD*Background: Disease Activity Score in 28 Joints (DAS28) is a scoring
system to evaluate disease activity and treatment response in rheumatoid
arthritis (RA). A DAS28 score of greater than 3.2 is a well-described limit
for treatment intensification; however, the reliability of DAS28 might
be overestimated.
Objective: The aim of this study was to evaluate the reliability of DAS28
in RA, especially focusing on a subgroup of patientswith a DAS28 score of
greater than 3.2.
Methods: Data from RA patients registered in the local part of Danish
DANBIO Registry were collected in May 2015. Patients were categorized
into 2 groups: First, those with DAS28 >3.2 with at least one swollen joint
(SJ) or elevated C-reactive protein (CRP) (“objective group”), and second,
patients with a DAS28 >3.2 who had no SJ, and CRP values were within
the reference range (“subjective group”). Disease Activity Score in 28
Joints, Clinical Disease Activity Index, and Health Assessment Question-
naire scores were calculated for each group.We defined new score, DAS28
subjective, to focus on subjective parameters.
Results: Two hundred thirty patients were included; 198 (86.1%) and 32
(13.9%) patients were in the objective and subjective groups, respectively.
Patients in the subjective group had lower mean values of DAS28
(P < 0.001) and Evaluator Global Assessment (P < 0.001) with less com-
mon immunoglobulin M rheumatoid factor (P < 0.001) and anti–cyclic
citrullinated peptide positivity (P = 0.02) and contrarily higher meanvalues
of tender joints (P = 0.04) and DAS28 based on subjective parameters
(P = 0.003) compared with the objective group.
Conclusions: Rheumatoid arthritis scoring systems should be used cau-
tiously in patientswho are considered for treatment intensification. Patients
with central sensitization and psychological problems and those with false-
positive diagnosis of RA are at high risk of overtreatment.From the *Department of Rheumatology, Odense University Hospital, Svendborg
Hospital, Svendborg; and †Faculty of Health Sciences, University of Southern
Denmark, Odense; ‡DANBIO Registry, Copenhagen; and §Department of
Technology and Innovation, University of Southern Denmark, Odense,
Denmark.
Ethical approval for this local study was sought from Danish Data Protection
Agency (file no. 15/25403). DANBIO has been approved by The Danish
Data Registry since the year 2000 (j. nr. 2007-58-0014 and j. nr. 2007-
58-0006) and since 2006 as a national quality registry by the National
Board of Health (j. nr. 7-201-03-12/1).
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R heumatoid arthritis (RA) is a chronic inflammatory poly-arthritis with a prevalence of 0.5% to 1% in the general popu-
lation.1 It has been accepted that initiating RA treatment at the
early stage of disease improves clinical outcomes and prevents
further joint destruction.2,3
Because of the variable expressions of RA, different indi-
ces have been defined to evaluate the disease activity and re-
sponse to treatment, for instance, Disease Activity Score in 28
Joints (DAS28) and Clinical Disease Activity Index (CDAI).4–6
Reaching the optimal control of RA requires regular evaluation
of inflammatory activity with the aim of these scores. The differ-
ent evaluations have advantages and disadvantages with respect to
the monitoring of the patients. Disease Activity Score in 28
Joints–C-reactive protein (CRP) is a scoring system that is widely
used to evaluate treatment efficacy and in monitoring disease ac-
tivity of RA patients in daily practice.7–9 It is calculated from 4 pa-
rameters: 2 of the parameters are subjective including tender joints
(TJs) (range, 0–28) and Patient Global Assessment (PGA) (range,
0–100), and 2 of them are objective components including swol-
len joints (SJs) (range, 0–28) and laboratory value of CRP.7,10 It
is continuous and ranges from 0.96 to maximum of 9.4 if CRP
up to 100 mg/L is considered.9 A DAS28 value of greater than
5.1 indicates highdisease activity. Thevalues of3.2<DAS28≤5.1
and DAS28 ≤ 3.2 are indicative of moderate and low disease ac-
tivities, respectively. If DAS28 value is less than 2.6, the patients
may be considered to be in remission phase.10–12 Clinical Disease
Activity Index is a valid measure of disease activity, based only on
clinical variables, calculated by the summation of TJs, SJs, PGA,
and Evaluator Global Assessment (EGA), which does not require
values of acute phase reactants, enhances its feasibility in routine
clinical practice, and facilitates assessment of disease activity and
treatment response.13 Health Assessment Questionnaire (HAQ) is
a criterion standard and the most commonly used tool to evaluate
functional status of RA patients.14
Disease Activity Score in 28 Joints can help clinicians to
make a decision to start/change/stop treatment with disease-
modifying antirheumatic drugs (DMARDs).4 Therefore, it should
be calculated precisely, whereas miscalculation of DAS28 score
results in incorrect patient classification and treatment plan.15 In
patients with high disease activity, it is advisable to change the treat-
ment, starting/intensifying/terminating DMARDs or initiating/
changing biologics because of lack of response, and in patients
with persistent low disease activity, clinicians should consider
minimizing or stopping DMARD treatment.4,16nal of Clinical Rheumatology • Volume 23, Number 2, March 2017
JCR: Journal of Clinical Rheumatology • Volume 23, Number 2, March 2017 Disease Activity Score in RAThe primary objective of the study was to evaluate the re-
liability of DAS28 in RA. The secondary objectives are to
find out how often the DAS28 score is higher than 3.2 in our pa-
tient population if the calculation is based only on subjective
parameters, as well as to compare clinical characteristic of this
group of patients with those who had DAS28 score of greater
than 3.2 with at least 1 objective parameter. At last, we discuss




The Danish DANBIO Registry was established in 2000 and
provides nationwide data on the disease course of patients with
inflammatory rheumatic disease including RA. Baseline vari-
ables, for example, demographic data, diagnosis, and diseases du-
ration, and longitudinal/follow-up data, for example, treatment,
functional status, and disease activity scores, are registered to
DANBIO.17 DANBIO has been approved by The Danish Data
Registry (j. nr. 2007-58-0014 and j. nr. 2007-58-0006) and the
National Board of Health (j. nr. 7-201-03-12/1).
Study Design and Setting
This was a cross-sectional, exploratory, registry-based, sin-
gle-center study. All parts of study were performed at the rheuma-
tology outpatient clinic. Ethical approval for our local study was
sought from Danish Data Protection Agency (file no. 15/25403).
Participants
Data from the last DANBIO registration of all RA patients
who were registered in the local part of DANBIO were extracted
in May 2015. Since 2010, diagnosis of RA has been established
according to the new 2010 American College of Rheumatology/
European League Against Rheumatism criteria for RA. Inclusion
criteria were as follows: (a) patients whowere registered in the de-
partment of rheumatology, (b) 18 years or older at diagnosis, and
(c) DAS28 score of greater than 3.2 on last DANBIO registration.
Data from the latest visit of patients who passed away or refereed
to the other departments were also obtained. Exclusion criteria
were incomplete information, that is, no CRP within 1 week prior
to or after the visit or no TJs and/or SJs entered; patients unable to
assess PGA (eg, severely disabled patients, dementia, etc); pa-
tients who consulted the outpatient emergency department to per-
form joint puncture and inject glucocorticoids as quickly asTABLE 1. Demographic Data and Disease Characteristics of All Inclu
All included Patients (n = 230) Obj
Age, mean ± SD, y 66.2 ± 15.3
Sex, n (%) Male: 74 (32.2)
Female: 156 (67.8)
IgM RF, n (%) Positive: 133 (57.8)
Negative: 54 (23.5
No data: 43 (18.7)
Anti-CCP, n (%) Positive:102 (44.3)
Negative:86 (37.4)
No data:42 (18.3)
DMARDs treatment, n (%) 178 (77.4)
Biologic treatment, n (%) 57 (24.8)
© 2016 The Author(s). Published Wolters Kluwer Health, Inc.possible; and those not fully registered in DANBIO, following
department policy.
After obtaining all included patients’ data, we identified 2
specific groups of patients: first, patients with at least 1 SJ or ele-
vated CRP (“objective group”), and second, patients who had no
SJ and whose CRP values were less than 6 mg/L (reference range,
<6 mg/L) (“subjective group”).
Data Collection and Variables
Patients’ demographic data (age and gender), disease charac-
teristics (TJs, SJs, immunoglobulin M [IgM] rheumatoid factor
[IgM RF], and anti–cyclic citrullinated peptide [anti-CCP]), labo-
ratory results of CRP, PGA, EGA, and treatment plan (DMARDs,
biologics) were extracted from DANBIO. The current PGA and
the items in the HAQ score were entered into the database by pa-
tients in the waiting room, just before they came into the physi-
cians’ consultation. The results of radiological evaluations for
patients in the subjective group were also gathered.
A 100-mm visual analog scale technique was used to mea-
sure PGA and EGA. Disease Activity Score in 28 Joints and
CDAI were calculated by using the following formulas:
DAS28 = 0.56 * √(TJ) + 0.28 * √(SJ) + 0.36 * ln(CRP + 1) +
0.014 * PGA + 0.96 (can be interpreted as low disease activity:
DAS28 ≥2.6 and ≤3.2, moderate disease activity: DAS28 >3.2
and ≤5.1, and high disease activity: DAS28 >5.1).
CDAI = SJs + TJs + PGA + EGA (can be interpreted as low
disease activity: CDAI >2.8 and ≤10, moderate disease activity:
CDAI >10 and ≤22, and high disease activity: CDAI >22).
The Stanford Health Assessment Questionnaire was used to
measure HAQ score. It ranges between 0 and 3, with 0 indicating
no impairment and 3 indicating completely impaired.
In addition to the previously mentioned variables, we defined
a new variable, DAS based on subjective parameters (DAS28s), to
focus on the subjective parameters. It was calculated as follows:
DAS28s = 0.56 * √ (TJ) + 0.014 * PGA.
DMARDs and Biologics
Disease-modifying antirheumatic drugs include methotrexate,
sulfasalazine, hydroxychloroquine, azathioprine, and leflunomide,
andbiologics include etanercept, adalimumab, infliximab, certolizumab
pegol, abatacept, tocilizumab, golimumab, and rituximab.
Statistical analysis
All statistical analyses were performed using Microsoft
Excel 2010 (Version 14.0.7173.5000; Microsoft Corp, Redmond,ded Patients and the “Objective” and “Subjective” Groups
ective Group (n = 198) Subjective Group (n = 32) P (χ2)
66.9 ± 15.0 61.9 ± 16.0 0.11
Male: 66 (33.3) Male: 8 (25) 0.42
Female: 132 (66.7) Female: 24 (75)
Positive: 121 (61.1) Positive: 12 (37.5) <0.001
Negative: 35 (17.7) Negative: 19 (59.4)
No data: 42 (21.2) No data: 1 (3.1)
Positive: 91 (46) Positive: 11 (34.4) 0.02
Negative: 65 (32.8) Negative: 21 (65.6)
No data:42 (21.2) No data: 0 (0)
151 (76.3) 27 (84.4) —
48 (24.2) 9 (28.1) —
www.jclinrheum.com 103
TABLE 2. Comparison of Tender Joint Count, Patient Global Assessment, Evaluator Global Assessment, Functional Status, and
Different Disease Activity Indices Between the Objective and Subjective Groups
Objective Group (n = 198) Subjective Group (n = 32) P (t Test)
TJs 7.4 ± 7.1 10.1 ± 6.3 0.04
PGA 56.4 ± 22.7 57.8 ± 19.6 0.73
EGA 20.8 ± 15.2 10.7 ± 7.7 <0.001
DAS28 4.4 ± 0.9 3.9 ± 0.5 <0.001
HAQ 1.2 ± 0.8 1.3 ± 0.7 0.54
CDAI 15.4 ± 10.2 14.7 ± 6.9 0.63
DAS28s 2.2 ± 0.8 2.50 0.003
Hansen et al JCR: Journal of Clinical Rheumatology • Volume 23, Number 2, March 2017Washington DC). Continuous data are presented as mean ± SD,
and categorical data as frequencies and respective percentages.
Comparisons of the previously mentioned variables between ob-
jective and subjective groups were madewith Student t test. When
comparing 2 binary variables, a χ2 test was performed. P ≤ 0.05
was considered significant. Correlations between variables were ana-
lyzed using correlation coefficient test. We considered the follow-
ing values in interpreting correlation results: high correlation,
≥0.7; moderate correlation, ≥0.5 and <0.7; low correlation,
≥0.3 and <0.5; and no correlation, <0.3. In case of missing data,
we used pairwise deletion to keep as many cases as possible for
each analysis.
RESULTS
Eight hundred seventy-six RA patients were registered in the
local part of DANBIO. Of 876 patients, 230 patients fulfilled the
inclusion, and none of the exclusion criteria. One hundred ninety-
eight (86.1%) and 32 (13.9%) patients were in the objective and
subjective groups, respectively. Table 1 summarizes the demo-
graphic data and disease characteristics, as well as treatment mo-
dality, for all included patients and the objective and subjective
groups (Table 1). Patients were treated with DMARDs and bio-
logics alone or in various combinations. Immunoglobulin M RF
and anti-CCP positivity were significantly less common in the
subjective group.
The mean values of TJs and DAS28s in the subjective group
were significantly higher than those in the objective group. Themean
value of PGAwas higher in the subjective group; however, the differ-
encewas not statistically significant. Furthermore, DAS28 and EGA
were significantly higher in the objective group. Although the
mean value of CDAI in the objective group (15.4 ± 10.2) was
higher than that in the subjective group (14.7 ± 6.9), the difference
was not statistically significant (Table 2).
Health Assessment Questionnaire was correlated (low to al-
most moderate) to TJs, PGA, CDAI, DAS28, and DAS28s inTABLE 3. Results of Correlation Analysis Between Different











104 www.jclinrheum.comthe objective group; however, we did not find any correlations
between HAQ and TJs, as well as PGA, CDAI, DAS28, and
DAS28s, in the subjective group (Table 3).
Of 32 patients in the subjective group, 29 patients had no ab-
normal radiographic findings (Table 4). Eighteen of 32 patients in
this group were negative for both IgM RF and anti-CCP without
positive findings on the radiological evaluations.
DISCUSSION
In the present study, of 230 included patients, 32 patients
(13.91%) were categorized into the subjective group with DAS28
higher than 3.2 and no objective findings compared with 198
(86.1%) in the objective group. There were significant differences
between disease characteristics (IgMRFand anti-CCP), TJs, EGA,
DAS28, and DAS28s, as well as correlation analysis of patients, in
the objective and subjective groups, provoking thought that these
2 groups of patients belong to different populations.
Psychological diseases such as depression, anxiety, and
chronic fatigue are common in patients with RA.18,19 These con-
ditions can affect the course of RA disease and patients’ clinical
function, as well as PGA.20,21 In this study, we found that patients
in the subjective group had higher mean values of TJs and
DAS28s; however, they had lower mean value of DAS28. More-
over, in the subjective group, there were no correlations between
HAQ and TJs, PGA, CDAI, DAS28, and DAS28s, which could
be due to the relatively low number of the patients in this group,
but it also implies a less severe disease with better functional sta-
tus. Absence of radiographic findings in 29 patients of the subjec-
tive group also supports this hypothesis. Our clinical experience
showed that most of our patients in the subjective group were un-
responsive to treatment intensification over time and reported
more levels of pain and higher values of PGA. Therefore, we pro-
pose that reducing treatment or changing to nonsteroidal anti-
inflammatory drugs in a majority of patients, after strict individual
assessment, has the same effects. However, more studies are re-
quired to confirm this hypothesis.TABLE 4. Disease Characteristics and Radiographic Findings of







IgM RF positive, anti-CCP positive 3 6
IgM RF positive, anti-CCP negative 0 3
IgM RF negative, anti-CCP positive 0 2
IgM RF negative, anti-CCP negative 0 18
© 2016 The Author(s). Published Wolters Kluwer Health, Inc.
JCR: Journal of Clinical Rheumatology • Volume 23, Number 2, March 2017 Disease Activity Score in RACentral sensitization is a persistent state of hyperreactivity of
the nervous system. It usually presents in the forms of allodynia
(experiencing pain with nonpainful triggers) or hyperalgesia
(exaggerated and prolonged response to painful triggers) and con-
tributes to different clinical syndromes, for instance, RA, osteoar-
thritis, fibromyalgia, and so on. Patients with RA may experience
more severe amount of pain at both articular and nonarticular sites
in response to different triggers.22–24 Some of the patients in the
subjective group may be involved in the process of changing pain
sensitivity inducing central sensitization because the high number
of TJs and the poor relation between disease activity and symp-
toms are suggestive of the existence of central sensitization in this
group of patients; however, further studies in this field are re-
quired to confirm this hypothesis. We recommend that in doubtful
cases the newly introduced painDETECT questionnaire should be
applied to evaluate whether a pain sensitization has occurred. It is
a validated questionnaire and translated to different languages. Pa-
tients answer different questions regarding pain intensity. The
painDETECT score ranges from 0 to 38, in which a score of 19
or greater indicates that central sensitization has likely happened;
13 to 18, uncertain results; and a score of 12 or less shows that
central sensitization has unlikely occurred.24,25 It is particularly
relevant when rheumatologists is confronted with a patient with
few signs of inflammation prior to treatment initiation. A recent
study, evaluating nonnociceptive pain in RA, revealed that central
sensitization may occur frequently in a group of patients initiating
or intensifying treatment for their RA, which can result in in-
creased disease activity scores on a noninflammatory basis.26
In addition, earlier studies frequently showed that seroposi-
tive RA with high titers of autoantibodies and high CRP values
at diagnosis are associated with more destructive disease with
poorer outcome.27–29 In the present study, seropositivity was sig-
nificantly less common in the subjective group. This indicates that
patients in the subjective group had good prognosis in average,
and there would not be a great need for treatment intensification;
however, DAS28 was higher than 3.2.
The American College of Rheumatology/European League
Against Rheumatism new criteria for RA were published in
2010.2 A recent meta-analysis by Radner et al30 revealed that
the pooled sensitivity and specificity of the new criteria range
from 79% to 84% and 59% to 64%, respectively. This is about a
proportion of patients who received a diagnosis of RA but do
not have the disease (false positivity). We think that, in the present
study, there were some patients among the subjective group who
had a misdiagnosis of RA (false-positive diagnosis of RA),
while they suffer from another condition, for example, psycho-
logical diseases (depression, chronic fatigue pain, etc), as well as
other inflammatory joint diseases in the differential diagnosis of
RA. Thus, discordance between TJ count and PGA with disease
severity and poor response to treatment intensification would
be expected.
Another explanation for relatively high number of patients in
the subjective group without having SJs or elevated CRP is be-
cause in the calculation of DAS28 TJ count plays a more signifi-
cant role in comparison with SJ count. This is because in the
previously mentionedDAS28 formula, the square root of TJ count
multiplies by 0.56, whereas the square root of SJ count multiplies
by 0.28. As a consequence, TJ count can affect the final amount
twice as much as SJ count. Previouswork from our department re-
vealed that subjective parameters added together give a total of
58% the total DAS28. In addition, DAS28 can be as high as 5.7
without any objective findings indicating high disease activity.31
This shows the need for further improvement of DAS28 to make
it more accurate. We suggest that SJs should have a more impor-
tant role than TJs because it is more reliable.© 2016 The Author(s). Published Wolters Kluwer Health, Inc.A limitation of this study includes relatively low number of
patients in the subjective group because we had data from only
32 patients from which to perform data analysis. Furthermore, in
this study, patients in the objective groupwith elevated CRPmight
also belong to the subjective group because CRP could be in-
creased by the reason of infection or other causes. There might
contrarily be some patients in the subjective group who belong
to the objective group because of the dynamic characteristic of
RA, in whom swelling of the joints may fade before soreness.
The strength of the study is that all RA patients at the rheumatol-
ogy outpatient clinic were included in the study, which can mini-
mize selection bias. Information bias was not a problem in this
study; neither the investigating physicians nor the patients knew
that the investigation was planned. The results from this study
have a high degree of generalizability because of broad inclusion
criteria. In addition, these 2 groups of patients can be identified in
any rheumatologic departments.
In fact, there is a risk of overtreatment in RA patients with
central sensitization, patients with psychological problems, and
those with false-positive diagnosis of RA. Therefore, clinicians
should use RA scoring systems cautiously in patients who are
considered for treatment intensification. This is particularly true,
once the decision to start biological treatment has been made be-
cause of relative medical expenses. To conclude, we propose that
DMARD treatment should be tentatively stopped instead of being
intensified if patients in 2 consecutive visits have DAS28-CRP of
greater than 3.2 and the DAS28 calculation is based on subjective
parameters, the CRP is normal, and there is neither SJ nor radio-
graphic signs of arthritis, besides that IgM RF is low or negative.
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